The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-26 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
=== Generic names === Clomipramine is the English and French generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française, while clomipramine hydrochloride is its USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name. Clomipramina is its generic name in Spanish, Portuguese and Italian and its DCITTooltip Denominazione Comune Italiana, while clomipramin is its generic name in German and clomipraminum is its generic name in Latin.
== History == ACAM2000 is a vaccine developed by Acambis, which was acquired by Sanofi Pasteur in 2008, before selling the smallpox vaccine to Emergent Biosolutions in 2017. Six strains of vaccinia were isolated from 3,000 doses of Dryvax and found to exhibit significant variation in virulence. The strain with the most similar virulence to the overall Dryvax mixture was selected and grown in MRC-5 cells to make the ACAM1000 vaccine. After a successful Phase I trial of ACAM1000, the virus was passaged three times in Vero cells to develop ACAM2000, which entered mass production at Baxter. The United States ordered over 200 million doses of ACAM2000 in 1999–2001 for its stockpile, and production is ongoing to replace expired vaccine. Emergent Biosolutions developed ACAM2000 under a contract with the US Centers for Disease Control and Prevention (CDC). The US Food and Drug Administration (FDA) approved ACAM2000 in August 2007. By February 2008, it replaced Dryvax for all smallpox vaccinations. As of 2010, there were over 200 million doses manufactured for the US Strategic National Stockpile. According to the US FDA, "The approval and availability of this second-generation smallpox vaccine in the Strategic National Stockpile (SNS) enhances the emergency preparedness of the United States against the use of smallpox as a dangerous biological weapon." In August 2024, ACAM2000 was approved for mpox prevention in the United States.
BioShock received highly positive reviews from critics, with an average review score of 96/100 for Xbox 360 and Microsoft Windows, and 94/100 for PlayStation 3 on reviews aggregator Metacritic. Mainstream press reviews praised the immersive qualities of the game and its political dimension. The Boston Globe described it as "a beautiful, brutal, and disquieting computer game ... one of the best in years", and compared the game to Whittaker Chambers' 1957 riposte to Atlas Shrugged, "Big Sister Is Watching You". Wired also mentioned the Ayn Rand connection (a partial anagram of Andrew Ryan) in a report on the game which featured a brief interview with Levine. The Chicago Sun-Times review said "I never once thought anyone would be able to create an engaging and entertaining video game around the fiction and philosophy of Ayn Rand, but that is essentially what 2K Games has done ... the rare, mature video game that succeeds in making you think while you play". The Los Angeles Times review concluded: "Sure, it's fun to play, looks spectacular and is easy to control.
Sources: en.wikipedia.org
1-Benzoyl-DMT, also known as "DMT benzamide" or as 1-benzoyl-N,N-dimethyltryptamine, is a psychedelic drug of the tryptamine family related to dimethyltryptamine (DMT). It is the 1-benzoyl derivative of DMT. The drug is a prodrug of DMT with modified pharmacokinetic properties compared to DMT in rodents. It is assumed to be cleaved into DMT by amidase enzymes. Various analogues of 1-benzoyl-DMT that are likewise DMT or 5-MeO-DMT prodrugs have also been described and have shown widely varying pharmacokinetic parameters, for instance half-life. 1-Benzoyl-DMT was first described in the literature in a patent by Terran Biosciences in 2023. It has been one of the major prodrug compounds highlighted from the patent.
Congress reconvenes and formally certifies Joe Biden as the next president of the United States on the morning of January 7. President Trump formally concedes to an orderly transition of power to Joe Biden. During the Electoral College vote count, Senator Ted Cruz and Representative Paul Gosar object to Arizona's election results, the first time a vote is forced to accept or reject the objection since 2004. Representative Scott Perry and Senator Josh Hawley subsequently object to Pennsylvania's election results. January 7 Tesla and SpaceX CEO Elon Musk becomes the world's richest person, with a net worth exceeding $185 billion, surpassing Amazon CEO Jeff Bezos. Facebook indefinitely bans President Donald Trump from all of its platforms, citing his role in the January 6 Capitol riot. Twitter permanently suspends Trump's personal account the next day, January 8. Betsy DeVos resigns as Education Secretary in protest of President Trump's role in the January 6 Capitol riot. January 8 Amid an industry crackdown on extremist content following the January 6 Capitol riot, Google removes the mobile app of social networking service Parler from Google Play. Apple suspends the app from its App Store the next day, January 9. Parler goes offline a day later, January 10, when Amazon ceases to provide its cloud computing services. After 36 years, Alex Trebek's final episode of Jeopardy! airs. Ken Jennings becomes the temporary host on January 11 as the search for a new permanent host continues.
Alpha synuclein, having no single, well-defined tertiary structure, is an intrinsically disordered protein, with a pI value of 4.7, which, under certain pathological conditions, can misfold in a way that exposes its core hydrophobic residues to the intracellular milieu, thus providing the opportunity for hydrophobic interactions to occur with a similar, equally exposed protein. This could lead to self assembly and subsequent aggregation into large, insoluble fibrils known as amyloids. The conversion of soluble alpha synuclein into highly ordered, cross-β sheet, fibrillar structures does not, as previously thought, follow a two-step mechanism, rather, occurs through a series of transient, soluble oligomeric intermediates. In 2011, two groups published their findings that unmutated α-synuclein forms a stably folded tetramer that resists aggregation, asserting that this folded tetramer represented the relevant in vivo structure in cells, thereby relieving alpha synuclein of its disordered status. Proponents of the tetramer hypothesis argued that in vivo cross-linking in bacteria, primary neurons and human erythroleukemia cells confirmed the presence of labile, tetrameric species. However, despite numerous in-cell NMR reports demonstrating that alpha synuclein is indeed monomeric and disordered in intact E. coli cells, it is still a matter of debate in the field despite an ever growing mountain of conflicting reports.
=== March === 4 March – Banco Master scandal: The Supreme Federal Court orders the arrest of former Banco Master president and major shareholder Daniel Vorcaro in a potential fraud case worth up to 12 billion reais. The Federal Senate ratifies the EU–Mercosur Partnership Agreement. 5 March – A nursing home collapses in Belo Horizonte, killing eight people and leaving four missing. 10 March – Ski racer Cristian Ribera becomes the first athlete representing Brazil to win a medal in the Paralympics after achieving silver in the para-cross-country skiing men's seated sprint at the 2026 Winter Paralympics in Italy. 14 March – President Lula revokes the visa of US diplomat Darren Beattie after the latter tries to visit former president Jair Bolsonaro in prison. Three Israeli nationals are arrested after clashing with pro-Palestine demonstrators in Itacare. 17 March – A law restricting access to social media by minors comes into effect. 18 March – Eight people, including Comando Vermelho commander Claudio Augusto dos Santos, are killed in police raids across Rio de Janeiro. 20 March – Fernando Haddad resigns as finance minister after announcing that he would run for governor of Sao Paulo.
Sources: en.wikipedia.org
Although the negative health consequences of obesity in the general population are well supported by the available research evidence, health outcomes in certain subgroups seem to be improved at an increased BMI, a phenomenon known as the obesity survival paradox. The paradox was first described in 1999 in overweight and obese people undergoing hemodialysis and has subsequently been found in those with heart failure and peripheral artery disease (PAD). In people with heart failure, those with a BMI between 30.0 and 34.9 had lower mortality than those with a normal weight. This has been attributed to the fact that people often lose weight as they become progressively more ill. Similar findings have been made in other types of heart disease. People with class I obesity and heart disease do not have greater rates of further heart problems than people of normal weight who also have heart disease. In people with greater degrees of obesity, however, the risk of further cardiovascular events is increased. Even after cardiac bypass surgery, no increase in mortality is seen in the overweight and obese. One study found that the improved survival could be explained by the more aggressive treatment obese people receive after a cardiac event. Another study found that if one takes into account chronic obstructive pulmonary disease (COPD) in those with PAD, the benefit of obesity no longer exists.
== Variations == There are many variations possible while using the same basic concept of reducing the weight used. One way is to do a specified number of repetitions at each weight (without necessarily reaching the point of muscle failure) with an increase in the number of repetitions each time the weight is reduced. The amount or percentage of weight reduced at each step is also one aspect of the method with much variety. A wide drop set method is one in which a large percentage (usually 30% or more) of the starting weight is shed with each weight reduction. A tight drop set would remove anywhere from 10% to 25%. Drop sets may be performed either with or without rest periods between sets. Some make a distinction between the two: if the lifter does not rest then these sets are referred to as drop sets, whereas if the lifter does rest between sets then these sets are usually referred to as down sets. These definitions are somewhat arbitrary, of course, and not everyone will agree on the exact definitions.
== Malignant neoplasm of genitourinary organs (179–189) == 179 Malignant neoplasm of uterus, part unspecified 180 Malignant neoplasm of cervix uteri 181 Malignant neoplasm of placenta 182 Malignant neoplasm of body of uterus 182.0 Corpus uteri, except isthmus Endometrial cancer 183 Malignant neoplasm of ovary and other uterine adnexa 184 Malignant neoplasm of other and unspecified female genital organs 185 Malignant neoplasm of prostate 186 Malignant neoplasm of testis 187 Malignant neoplasm of penis and other male genital organs 188 Malignant neoplasm of bladder 189 Malignant neoplasm of kidney and other and unspecified urinary organs 189.0 Kidney, except pelvis Renal cell carcinoma
== Function == Mitochondrial creatine (MtCK) kinase is responsible for the transfer of high energy phosphate from mitochondria to the cytosolic carrier, creatine. It belongs to the creatine kinase isoenzyme family. It exists as two isoenzymes, sarcomeric MtCK (CKMT2) and ubiquitous MtCK, encoded by separate genes. Mitochondrial creatine kinase occurs in two different oligomeric forms: dimers and octamers, in contrast to the exclusively dimeric cytosolic creatine kinase isoenzymes. Ubiquitous mitochondrial creatine kinase has 80% homology with the coding exons of sarcomeric mitochondrial creatine kinase. Two genes located near each other on chromosome 15 (CKMT1A and CKMT1B (this gene)) have been identified which encode identical mitochondrial creatine kinase proteins.
=== Availability === Gonadorelin is available widely throughout the world for veterinary use, including in the United States, Canada, the United Kingdom, Ireland, elsewhere throughout Europe, South Africa, Australia, New Zealand, Japan, Taiwan. However, gonadorelin is not available for clinical use in humans in the United States.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.